BMY vs PFE: fair value comparison
Bristol-Myers Squibb Company and Pfizer Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our discount ranking. BMY carries the stronger quality grade.
| BMY | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $66.82 | $28.45 |
| 12-month range | $46.02–$66.92 | $24.23–$28.55 |
| Sector rank | #100 of 113 Healthcare | #101 of 113 Healthcare |
| Quality grade | C | F |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · PFE fair value analysis